Asia’s Evolving CGT Approvals and Access Landscape

Published in Cytotherapy (Review Article)

Asia’s CGT sector continues to expand with fast-track pathways in Japan, Korea, China and Singapore while India and Thailand advance through flexible access models and domestic innovation. Approvals for CAR-T, stem cell and gene therapies are rising and pricing differences highlight how local manufacturing and regulatory maturity shape affordability and access. Regional collaboration and shared infrastructure are identified as key levers for sustainable growth.

👉 Read the full article: Cell and gene therapy approvals in Asia: regulatory landscape, access and affordability (Cytotherapy, 2025)

Disclaimer:

Images used are for illustrative purposes only and do not depict actual persons, products or facilities. This post is for educational purposes only and the full details should be obtained from the original article. SSCTR does not provide medical advice.